EXHIBIT
10.4


 


EMPLOYMENT AGREEMENT


 


This employment agreement (the “Agreement”)
is entered into by and between Bassam Damaj, Ph.D. (“you” or “your”) and Innovus Pharmaceuticals, Inc.,
a Nevada corporation (the “Company”). This Agreement has an effective date of January 22, 2013 (the “Effective
Date”).


 


In consideration of the mutual covenants and
promises made in this Agreement, you and the Company agree as follows:


 


1.       Position and Responsibilities. As of the
Effective Date, you will be employed by the Company as the Company’s sole President and Chief Executive Officer (“PCEO”).
As PCEO, you shall report directly to the Company’s Board of Directors (the “Board”). You shall be the Company’s
most senior executive officer and shall have the duties, responsibilities and authority that are customarily associated with such
position. Your office will be located at the Company’s headquarters at 4275 Executive Square, Suite 207, San Diego CA, 92037.


 


You shall also serve as a member of the Board and the Company
agrees that, while you are employed by the Company and/or possess more than 1% of its outstanding stock, it will nominate you to
continue to serve as a member of the Board whenever your seat on the Board is up for re-election. Nothing herein shall preclude
you from (i) serving, with the prior written consent of the Company, as a member of the board of directors or advisory boards
(or their equivalents in the case of a non-corporate entity) of non-competing businesses and charitable organizations, (ii) engaging
in charitable activities and community affairs, and (iii) managing your personal investments and affairs. The Company hereby
acknowledges your ownership of (or relationship with) the entities identified in Exhibit A and consents to such ownership
or relationship for so long as such entities continue to be a non-competing business with the Company.


 


2.        Term. Your employment with the Company is
at-will and either you or the Company may terminate your employment at any time and for any reason, with or without Cause/Good
Reason (as each are defined below), in each case subject to the terms and provisions of this Agreement. Unless terminated earlier,
this Agreement will extend through the fifth anniversary of the Effective Date (“Expiration Date”); provided, however,
on such fourth anniversary of the Effective Date (and on each subsequent anniversary thereafter) the Expiration Date will automatically
be extended by an additional year unless either party has provided written notice to the other party before the applicable anniversary
that such party will not agree to so extend the Agreement.


 


3.       Salary, Bonus, Equity Incentives, Benefits and Indemnification.
For avoidance of doubt, the Board may delegate its authority and responsibilities under this Section 3 to a committee of members
of the Board.


 


(a)      Base Salary. Commencing on the
Effective Date, you will be paid an annual base salary of $375,000.00 (the “Base Salary”) for your services as PCEO,
payable in the time and manner that the Company customarily pays its employees provided that you will receive pro-rata payments
of Base Salary at least once each calendar month (subject to the going concern exception described below). On the first anniversary
on the Effective Date your Base Salary will be increased to $440,000 and it will continue at this rate through the day before the
second anniversary of the Effective Date. Your Base Salary shall also be reviewed periodically by the Board and may be increased
(but not decreased) by the Board provided however that in any event on each anniversary of the Effective Date (commencing on the
second anniversary of the Effective Date) your Base Salary shall increase by at least 10%. Notwithstanding the foregoing, to the
extent that payment of such Base Salary would jeopardize the Company’s ability to continue as a going concern, such payments
shall not be made and shall instead be accrued and paid to you when payment would no longer so jeopardize the Company. If payments
of Base Salary are accrued in accordance with the foregoing then such unpaid amounts shall be provided to you in cash upon the
earlier of the Board’s determination that payment can be made without so jeopardizing the Company or the date when the Company’s
auditors have determined that there is no longer substantial doubt about the Company’s ability to continue as a going concern
(such earlier date is the “Accrued Salary Payment Date”). The Company shall administer payment of the Base Salary to
at all times be in compliance with the short-term deferral provisions of Section 409A of the Internal Revenue Code of 1986 as amended
(the “Code”).


 






    	1



    	 



    

 


(b)      Bonuses. You will be eligible
to participate in any bonus programs as set forth by the Board. In addition, during each Company fiscal year you will be eligible
to earn an annual cash bonus based on performance objectives reasonably established by the Board and after considering input from
you and which will be communicated in writing to you within the first 75 days of the applicable fiscal year. Your annual target
cash bonus amount will be equal to 75% of your then annual Base Salary rate (with such rate determined as of the day after the
applicable anniversary of the Effective Date for such fiscal year). The actual amount of the annual bonus paid to you, if any,
shall be determined by the Board in its sole discretion and may be more or less than the target amount. If your employment ends
during any given fiscal year for any reason and whether or not you execute the Mutual Release described in Section 6(d), you will
be paid a pro-rata amount of the target bonus determined by the percentage of time you were employed during the fiscal year. If
your employment ends for any reason after the completion of a fiscal year but before the payment of the annual bonus and whether
or not you execute the Mutual Release described in Section 6(d), you shall remain eligible to receive the full bonus amount based
on achievement of the applicable performance objectives. In all cases, any such bonus shall be paid to you during the first two
and a half months of the fiscal year that follows the applicable performance fiscal year.


 


(c)      Compensatory Equity. The Company
shall grant you restricted Stock Units (“RSU”) covering 6,000,000 shares of the Company’s common stock (the “RSU
Grant”). 2,000,000 shares of the RSU Grant shall be vested at grant. Subject to your continued Service, the remaining 4,000,000
shares shall vest in eight pro-rata equal installments on a quarterly basis over the following two years with the first such installment
occurring on April 1, 2013. The vested portion of the RSU Grants shall be settled with a like number of Company common shares on
the earlier of (i) your Termination Date, (ii) a Change in Control of the Company (as defined below), or (iii) the seventh anniversary
of the Effective Date. The RSU Grant shall be granted to you as soon as practicable after the Company has filed with the Securities
and Exchange Commission an effective registration statement covering the RSU Grant and its underlying shares.


 


For purposes of this Agreement, the RSU Grant
and any other Company compensatory equity grants issued to you shall be collectively referred to herein as “Compensatory
Equity”. To the extent you receive any stock options, stock appreciation rights or similar derivative securities, you shall
be entitled to exercise the vested portion of such awards until the earliest of the tenth anniversary of the grant date of the
award or the third anniversary of your Termination Date (as defined below). In connection with any award of Compensatory Equity
(including the RSU Grant), you shall be permitted at your election to satisfy the applicable exercise price and/or tax withholding
obligations via share withholding with the shares that are surrendered to the Company valued at their then fair market value as
of the applicable vesting or settlement date(s).


 


You shall be eligible for additional grants
of Compensatory Equity in order to ensure that you have competitive equity compensation. All grants of Compensatory Equity shall
be issued pursuant to: (i) a Board-approved employee stock incentive plan (the “Plan”) and (ii) an effective registration
statement filed (and maintained) by the Company with the Securities and Exchange Commission in accordance with the Securities Act
of 1933, as amended.


 


Additionally, all outstanding unvested Compensatory
Equity awards shall fully vest and become exercisable (to the extent exercise is required) upon the earlier of a Change in Control
occurring during your Service (as defined below). You may also elect to establish a trading plan for Company securities in accordance
with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). For purposes of this Agreement
and your Compensatory Equity, “Service” shall mean service by you as an employee, director and/or consultant of the
Company (or any subsidiary or parent or affiliated entity of the Company).


 


(d)      Benefits. Commencing with the
Accrued Salary Payment Date, you will be entitled to participate, on no less favorable terms provided to any other Company officer,
in all Company employee benefit plans and programs at the time or thereafter made available to Company senior executive officers
including, without limitation, any savings or profit sharing plans, deferred compensation plans, stock option incentive plans,
group life insurance, accidental death and dismemberment insurance, hospitalization, surgical, major medical and dental coverage,
vacation, sick leave (including salary continuation arrangements), long-term disability, holidays and other employee benefit programs
sponsored by the Company. On and after the Accrued Salary Payment Date, the Company will provide you with life insurance coverage
for the benefit of your heirs with a face amount of not less than two times your Base Salary that is in effect as of the Effective
Date.


 






    	2



    	 



    

  


Notwithstanding the foregoing, commencing
with the Effective Date and thereafter on each anniversary of the Effective Date, you shall incrementally accrue 30 days of paid
vacation time. Such accrued vacation time will not be subject to any maximum accrual limits and any unused portion shall be paid
to you in cash on your last day of employment with the Company applying your then annual Base Salary rate. Moreover, when you travel
on Company business, you shall be entitled to fly in first class on international flights and on business class for domestic flights.
Additionally, the Company shall pay for you to maintain club memberships with American Airlines, United Airlines and Delta and
other major airline clubs commencing on the Effective Date and continuing through the second anniversary of your Termination Date.


 


(e)      Indemnification. In the event
that you are made a party or threatened to be made a party to any action, suit, or proceeding, whether civil, criminal, administrative,
or investigative (a “Proceeding”), by reason of your employment with, or serving as an officer or director of, the
Company, the Company shall indemnify and hold you harmless, and defend you to the fullest extent authorized by the laws of the
state in which the Company is incorporated, as the same exist and may hereafter be amended, against any and all claims, demands,
suits, judgments, assessments, and settlements (collectively the “Claims”), including all expenses incurred or suffered
by you in connection therewith and such indemnification shall continue as to you even after you are no longer providing Service,
and shall inure to the benefit of your heirs, executors, and administrators. The Company shall have the right to undertake, with
counsel or other representatives of its own choosing, the defense or settlement of any Claims. In the event that the Company shall
fail to notify you, within ten days of its receipt of your written notice, that the Company has elected to undertake such defense
or settlement, or if at any time the Company shall otherwise fail to diligently defend or pursue settlement of such Claims, then
you shall have the right to undertake the defense, compromise, or settlement of such Claims, in which event the Company shall hold
you harmless from any legal fees incurred by you for your counsel. Neither you nor the Company shall settle any Claims without
the prior written consent of the other, which consent shall not be unreasonably withheld or delayed. Regardless of which party
is conducting the defense of any such Claims, the other party, with counsel or other representatives of its own choosing and at
its sole cost and expense, shall have the right to consult with the party conducting the defense of such Claims and its counsel
or other representatives concerning such Claims and you and the respective counsel or other representatives shall cooperate with
respect to such Claims. The party conducting the defense of any such Claims and its counsel shall in any case keep the other party
and its counsel (if any) fully informed as to the status of such Claims and any matters relating thereto. You and the Company shall
provide to the other such records, books, documents, and other materials as shall reasonably be necessary for each to conduct or
evaluate the defense of any Claims, and will generally cooperate with respect to any matters relating thereto. This Section 3(d)
shall remain in effect after this Agreement is terminated, regardless of the reasons for such termination. The indemnification
provided to you pursuant to this Section 3(d) shall not supersede or reduce any indemnification provided to you under any separate
agreement, or the By-Laws of the Company; in this regard, it is intended that this Agreement shall expand and extend your rights
to receive indemnification. The Company shall maintain a directors and officers liability insurance policy (including coverage
through the sixth anniversary of cessation of all of your services to the Company) covering you in your capacity as an officer
and director of the Company and any Company affiliate.


 


4.      Expense Reimbursement. You will be promptly
reimbursed for all reasonable business expenses (including, but without limitation, travel expenses) upon the properly completed
submission of requisite forms and receipts to the Company.


 


5.      Change in Control (a)
Definition. For purposes of this Agreement, “Change in Control” shall mean a “change in control event”
as defined under Treasury Regulation Section 1.409A-3(i)(5)) as in effect on the Effective Date or any change in control definition
provided by the Plan.


 


(b)      Code Section 280G. In the event
that it is determined that any payment or distribution of any type to or for your benefit made by the Company, by any of its affiliates,
by any person who acquires ownership or effective control or ownership of a substantial portion of the Company’s assets (within
the meaning of Section 280G of the Code or by any affiliate of such person, whether paid or payable or distributed or distributable
pursuant to the terms of this Agreement or otherwise (the “Total Payments”), would be subject to the excise tax imposed
by Section 4999 of the Code or any interest or penalties with respect to such excise tax (such excise tax, together with any such
interest or penalties, are collectively referred to as the “Excise Tax”), then such payments or distributions or benefits
shall be payable either:


 






    	3



    	 



    

  


(i)      in full; or


 


(ii)      as to the maximum value of such
lesser amount which would result in no portion of such payments or distributions or benefits being subject to the Excise Tax.


 


You shall receive the greater, on an after-tax
basis, of (i) or (ii) above.


 


If the Total Payments must be reduced as provided
in the previous paragraph, the reduction shall occur in the following order: (1) reduction of cash payments for which the full
amount is treated as a "parachute payment" (as defined under Code Section 280G and its regulations); (2) cancellation
of accelerated vesting (or, if necessary, payment) of cash awards for which the full amount in not treated as a parachute payment;
(3) reduction of any continued employee benefits and (4) cancellation of any accelerated vesting of equity awards. In selecting
the equity awards (if any) for which vesting will be reduced under clause (4) of the preceding sentence, awards shall be selected
in a manner that maximizes the after-tax aggregate amount of reduced Total Payments provided to you, provided that if (and only
if) necessary in order to avoid the imposition of an additional tax under Section 409A of the Code, awards instead shall be selected
in the reverse order of the date of grant. For the avoidance of doubt, for purposes of measuring an equity compensation award's
value to you when performing the determinations under the preceding paragraph, such award's value shall equal the then aggregate
fair market value of the vested shares underlying the award less any aggregate exercise price less applicable taxes. Also, if two
or more equity awards are granted on the same date, each award will be reduced on a pro-rata basis.


 


All mathematical determinations and all determinations
of whether any of the Total Payments are parachute payments that are required to be made under this Section 5(b), shall be made
by a nationally recognized independent audit firm selected by the Company (the “Accountants”), who shall provide their
determination, together with detailed supporting calculations regarding the amount of any relevant matters, both to the Company
and to you. Unless you consent in writing, the Accountants may not be an audit firm that is then providing services in any capacity
to the person or entity that is acquiring the Company. Such determinations shall be made by the Accountants using reasonable good
faith interpretations of the Code. As expressly permitted by Treasury Regulations section 1.280G-1 Q/A-32, with respect to performing
any present value calculations that are required in connection with this Section 5(b), you and the Company each affirmatively elect
to utilize the Applicable Federal Rates ("AFR") that are in effect as of the Effective Date and the Accountants shall
therefore use such AFRs in their determinations and calculations. If the Accountants determine that no excise tax under Section
4999 of the Code is payable with respect to a Total Payment, it shall furnish the Company and you with an opinion reasonably acceptable
to you that no such excise tax under Section 4999 of the Code will be imposed with respect to such Total Payments. The Company
shall pay the fees and costs of the Accountants which are incurred in connection with this Section 5(b).


 


6.      Consequences of Termination of Employment.
For purposes of this Agreement, your last day of employment with the Company is the “Termination Date”. Upon termination
of your employment for any reason, you shall receive payment or benefits from the Company covering the following: (i) all
unpaid salary and unpaid vacation accrued through the Termination Date, (ii) any payments/benefits to which you are entitled
under the express terms of any applicable Company employee benefit plan, (iii) any unreimbursed valid business expenses for
which you have submitted properly documented reimbursement requests (iv) your then outstanding Compensatory Equity as governed
by their applicable terms and (v) a new computer laptop, new cell phone and new Pad (or similar device) commensurate in quality
with the devices you held immediately before the Termination Date (collectively, (i) through (v) are the “Accrued
Pay”). Except if your employment was terminated by the Company for Cause, you may continue to serve on the Board after your
Termination Date.


 


After termination of your employment for any reason and whether
or not the Mutual Release described in Section 6(d) is executed by you, the Company shall pay the entire premiums for your Company
group medical, dental and vision insurance coverage for you and your dependents for 12 months after the Termination Date with coverage
no less favorable than as of immediately before your Termination Date (the “Continuing Health Coverage”). If it becomes
unreasonable for the Company to continue to pay for this Continuing Health Coverage for you (or imposes adverse tax consequences
on you) because of changes in applicable law then the Company shall make the premium payments to you on an after-tax basis.


 






    	4



    	 



    

  


You will also be eligible for other post-employment payments
and benefits as provided in this Agreement including without limitation any unpaid bonus amounts described in Section 3(b). Within
no later than 90 days after the later of your Termination Date or the date that you are not considered to be a ten percent shareholder
under Section 16 of the Exchange Act, you shall no longer be considered a Company affiliate and the Company shall use commercially
reasonable efforts to facilitate the timely removal of any restrictive legends on any shares of Company common stock then held
by you.


 


(a)      For Cause. For purposes of this
Agreement, your employment may be terminated by the Company for “Cause” as a result of the occurrence of one or more
of the following:


 


(i)      Your commission of fraud or other
unlawful conduct in your performance of duties for the Company;


 


(ii)      Your conviction of, or a plea of
“guilty” or “no contest" to, a felony under the laws of the United States or any state thereof, if such
felony either is work-related or materially impairs your ability to perform services for the Company; or


 


(iii)      Your willful material breach of
this Agreement.


 


For purposes of the foregoing, no act, or
failure to act, on your part shall be considered “willful” unless done, or omitted to be done, by you other than in
good faith, and without reasonable belief that your action or omission was in furtherance of the interests of the Company. The
foregoing shall is an exclusive list of the acts or omissions that shall be considered “Cause” for the termination
of your employment by the Company. The Board shall provide you with 30 days advance written notice specifically detailing the basis
(and factual circumstances) for the termination of your employment for Cause. During the 30 day period after you have received
such notice, you shall have an opportunity to cure or remedy such alleged Cause events and to present your case to the full Board
(with the assistance of your own counsel). A termination shall be deemed for Cause only if, following such 30 day period, at least
75% of the group consisting of the members of the Board other than you vote affirmatively that your termination is for Cause. You
shall continue to receive all of the compensation and benefits provided by this Agreement during the 30 day cure/remedy period.


 


(b)      Without Cause or for Good Reason
or Death or Disability. The Company may terminate your employment without Cause or for Disability at any time with thirty days
advance written notice or you may resign your employment for Good Reason (as defined below in Section 6(b)(iii)) or your employment
may also be terminated due to your death or by you due to your Disability (each of the foregoing, a “Qualifying Termination”).
Any notice of termination by the Company that is not covered by Section 6(a) must specify whether it was a termination without
Cause or due to your Disability. Without your prior written consent, once the Company has provided you with such a notice of termination
under this Section 6(b) then it may not rescind such notice nor may it modify the terms of your severance benefits described in
this Agreement. For purposes of this Agreement, “Disability” is defined to occur when you are unable to engage in any
substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result
in death or which has lasted or can be expected to last for a continuous period of not less than twelve (12) months. If your employment
is terminated due to a Qualifying Termination, then you will be eligible to receive the following benefits subject to your timely
compliance with Section 6(d) and further provided that no payments for such Qualifying Termination shall be made until
on or after the date of a “separation from service” within the meaning of Code Section 409A:


 


(i)      The Company shall provide you with
a cash payment equal in the aggregate to the product of 1.5 multiplied by the sum of your then annual Base Salary and your annual
target bonus amount (the “Severance Payment”). However, if your Termination Date occurs during the 24 months after
a Change in Control of the Company then the Severance Payment shall instead equal two times the sum of your then annual Base Salary
and your annual target bonus amount. The Severance Payment shall be paid to you in a single cash lump sum payment within fifteen
days following the effective date of the Mutual Release described in Section 6(d). To the extent necessary to comply with Code
Section 409A, if the timing of when you execute the Mutual Release would affect which tax year that such Severance Payment could
be paid then the Severance Payment shall be paid in the second tax year.


 


(ii)      The Company shall provide the Continuing
Health Coverage (or coverage no less favorable to you than the Continuing Health Coverage) for 24 months after the Termination
Date (rather than for only 12 months after the Termination Date). If it becomes unreasonable for the Company to continue to pay
for this Continuing Health Coverage for you (or it imposes adverse tax consequences on you) because of changes in applicable law
then the Company shall make the premium payments to you on an after-tax basis. Additionally, all outstanding unvested Compensatory
Equity awards shall fully vest and become exercisable (to the extent exercise is required) as of your Termination Date.


 


(iii)      For purposes of this Agreement,
you may resign your employment from the Company for “Good Reason” within one year after the date that any one of the
following events described in subparts (1) through (5) (any one of which will constitute “Good Reason”) has first
occurred without your written consent. Your resignation for Good Reason will only be effective if the Company has not cured or
remedied the Good Reason event within 30 days after its receipt of your written notice of the Good Reason event. Such notice of
your intention to resign for Good Reason must be provided to the Company within 90 days of the initial existence of a Good Reason
event. This “Good Reason” definition and process is intended to comply with the safe harbor provided under Treasury
Regulation Section 1.409A-1(n)(2)(ii) and shall be interpreted accordingly.


 


		(1)	You have incurred a material diminution in your responsibilities, duties or authority (it shall be deemed to be a material
diminution of your duties, authority or responsibilities if you are no longer a member of the Board (other than due to your voluntary
resignation from the Board or death or Disability) or are no longer the sole PCEO of the Company (or if the Company has a parent
entity, then you must be its sole PCEO and a member of the board of directors of the Company’s ultimate parent entity));



 


		(2)	Your workplace has been relocated to a new location that is more than 25 miles away from your work location that is specified
in Section 1;



 


		(3)	Any material reduction of your Base Salary or target bonus amount;



 


		(4)	The Company does not extend the Expiration Date of this Agreement as provided in Section 2; or



 


		(5)	The Company has materially breached any provision of this Agreement including without limitation the failure to timely pay
you the compensation or benefits owed to you under this Agreement.



 


You shall not be required to mitigate the
amount of any payment or benefit contemplated by this Section 6(b), nor shall any such payment or benefit be reduced by any earnings
or benefits that you may receive from any other source. If any cash payments that are owed to you under this Agreement are not
paid to you within fifteen days of their due date, then the Company will additionally owe you interest on such late payments, payable
on a monthly basis while any overdue amount is still outstanding, with interest accruing at the then prevailing prime rate, compounded
daily.


 


(c)      Voluntary Termination. In the
event you voluntarily terminate your employment with the Company without Good Reason and not due to Disability, you will not be
entitled to the Severance Payment but will receive your Accrued Pay plus the other post-termination payments that are not predicated
on a Qualifying Termination. You agree to provide the Company with at least 15 days advance written notice of your intention to
resign without Good Reason.


 


(d)      Mutual Release of Claims. Subject
to the next sentence, as a condition to receiving (and continuing to receive) the payments and benefits provided in Section 6(b),
you must within not later than forty-five (45) days after your Termination Date, execute (and not revoke) and deliver to the
Company a Mutual Release Of All Claims And Covenant Not To Sue agreement (the “Mutual Release”) in the form attached
as Exhibit B hereto. However, this requirement for you to provide an executed Mutual Release shall not be applicable if your employment
was terminated due to your death or Disability. The Company shall have the obligation to prepare and execute said Mutual Release
and tender such Company-executed Mutual Release to you on or before your Termination Date.


 






    	5



    	 



    

 


7.      Proprietary Information and Inventions Agreement;
Confidentiality. You will be required, as a condition of your employment with the Company, to execute the Company’s
form of proprietary information and inventions agreement (“Confidentiality Agreement”).


 


8.      Assignability; Binding Nature. Commencing
on the Effective Date, this Agreement will be binding upon you and the Company and your respective successors, heirs, and assigns.
This Agreement may not be assigned by you except that your rights to compensation and benefits hereunder, subject to the limitations
of this Agreement, may be transferred by will or operation of law. No rights or obligations of the Company under this Agreement
may be assigned or transferred except in the event of a merger or consolidation in which the Company is not the continuing entity,
or the sale or liquidation of all or substantially all of the assets of the Company provided that the assignee or transferee is
the successor to all or substantially all of the assets of the Company and expressly in writing assumes the Company’s obligations
under this Agreement. The Company will require any such purchaser, successor or assignee to expressly assume and agree to perform
this Agreement in the same manner and to the same extent that the Company would be required to perform if no such purchase, succession
or assignment had taken place. Your rights and obligations under this Agreement shall not be transferable by you by assignment
or otherwise provided, however, that if you die, all amounts then payable to you hereunder shall be paid in accordance with the
terms of this Agreement to your devisee, legatee or other designee or, if there be no such designee, to your estate.


 


9.      Governing Law; Arbitration. This Agreement
will be deemed a contract made under, and for all purposes shall be construed in accordance with, the laws of California.


 


Except as may be permitted below on this section 9, the parties
agree that any dispute between the parties arising out of or relating to the negotiation, execution or performance of this Agreement
shall be settled by expedited binding arbitration in accordance with the Employment Arbitration Rules and Mediation Procedures
of the American Arbitration Association. The location for the arbitration shall be San Diego, California. The arbitration award
shall be made within sixty (60) days of the filing of the notice of intention to arbitrate (demand), and the arbitrator(s) shall
agree to comply with this schedule before accepting appointment. Any award made by such arbitrator(s) shall be final, binding and
conclusive on the parties for all purposes, and judgment upon the award rendered by the arbitrators may be entered in any court
having jurisdiction thereof. The parties each agree that the arbitration provisions of this Agreement shall provide each party
with its exclusive remedy, and each party expressly waives any right it might have to seek redress in any other forum, except as
otherwise expressly provided in this Agreement. By electing arbitration as the means for final settlement of all claims, the parties
hereby waive their respective rights to, and agree not to, sue each other in any action in a Federal, State or local court with
respect to such claims, but may seek to enforce in court an arbitration award rendered pursuant to this Agreement. The parties
specifically agree to waive their respective rights to a trial by jury, and further agree that no demand, request or motion will
be made for trial by jury. In the event that either party brings an action under Section 9 to enforce or effect its rights under
or relating to this Agreement (a “Proceeding”), the prevailing party shall be entitled to recover its costs and expenses,
including the costs of mediation, arbitration, litigation, court fees, and reasonable attorneys’ fees incurred in connection
with such an action. The Company shall pay for all arbitration-specific costs.


 


If you are determined by the arbitrator to be the prevailing
party in any Proceeding where the Company was found to have materially breached this Agreement, then, in addition to being awarded
your costs and expenses, you shall be entitled to: (i) interest on any late payments, calculated at a rate equal to the Prime Rate
(as then quoted in the Wall Street Journal), compounded daily, and (ii) the acceleration of payment for all remaining payments
owed to you, so that the unpaid balance (including accrued interest) shall be paid in a single lump sum within ten business days
of the issuance of the arbitrator’s award. You may also be awarded any economic damages arising from the Company’s
breach, as may be determined in the arbitrator in the Proceeding.


 


In addition to the remedies set forth above, the parties hereby
agree that they shall be entitled to enforce their rights under this Agreement specifically (without posting a bond or other security).
All such rights and remedies shall be cumulative and non-exclusive, and may be exercised singularly or concurrently. The parties
agree that irreparable harm would occur in the event that any of the provisions of this Agreement were not performed in accordance
with their specific terms or were otherwise breached. Each party agrees that, in the event of any breach or threatened breach by
any other party of any covenant or obligation contained in this Agreement, the non-breaching party shall be entitled to seek and
obtain: (i) a decree or order of specific performance to enforce the observance and performance of such covenant or obligation,
and (ii) an injunction restraining such breach or threatened breach.


 






    	6



    	 



    

  


10.      Taxes. All payments made by the Company
hereunder to you or your estate or beneficiaries will be subject to tax withholding pursuant to any applicable laws or regulations.
This Agreement and its payments are intended to be exempt from or comply with the requirements of Code Section 409A and the Company
shall use its best efforts to ensure that there are no violations of Code Section 409A. If any taxes under Code Section 409A are
imposed on you, then the Company shall within thirty days of the determination that there would be an imposition of such taxes
provide you with a payment that will cover the costs of any Code Section 409A taxes, excise taxes, penalties and interest along
with any taxes imposed on such payment so that you will on an after-tax basis (applying the then highest aggregate marginal tax
rates) be no worse off than if no Code Section 409A taxes, excise taxes, penalties or interest had been imposed. Notwithstanding
any provision in the Agreement to the contrary, if upon your “separation from service” within the meaning of Code Section
409A, you are then a “specified employee” (as defined in Code Section 409A), then to the extent necessary to comply
with Code Section 409A and avoid the imposition of taxes under Code Section 409A, the Company shall defer payment of “nonqualified
deferred compensation” subject to Code Section 409A payable as a result of and within six (6) months following such “separation
from service” under this Agreement until the earlier of (i) the first business day of the seventh month following your “separation
from service,” or (ii) ten (10) days after the Company receives notification of your death. Additionally, the reimbursement
of expenses or in-kind benefits provided pursuant to this Agreement shall be subject to the following conditions: (1) the expenses
eligible for reimbursement or in-kind benefits in one taxable year shall not affect the expenses eligible for reimbursement or
in-kind benefits in any other taxable year; (2) the reimbursement of eligible expenses or in-kind benefits shall be made promptly,
subject to the Company’s applicable policies, but in no event later than the end of the year after the year in which such
expense was incurred; and (3) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for
another benefit. The provisions of this Section 10 shall survive any termination of this Agreement or your employment.


 


11.      Entire Agreement. Except as otherwise specifically
provided in this Agreement, this Agreement contains all the legally binding understandings and agreements between you and the Company
pertaining to the subject matter of this Agreement and supersedes all such agreements, whether oral or in writing, previously entered
into between the parties. In the event of any conflict in terms between this Agreement and any other agreement executed by and
between you and the Company or any Company plan or policy, the terms of this Agreement shall prevail and govern.


 


12.      No Offset or Mitigation. No severance or
other payments or benefits made to you under this Agreement may be offset by the Company or by any other party. You shall have
no duty of mitigation with respect to any severance or other payments or benefits made to you under this Agreement.


 


13.      Notice. Any notice that the Company is
required to or may desire to give you shall be given by personal delivery, recognized overnight courier service, email, telecopy
or registered or certified mail, return receipt requested, addressed to you at your address of record with the Company, or at such
other place as you may from time to time designate in writing. Any notice that you are required or may desire to give to the Company
hereunder shall be given by personal delivery, recognized overnight courier service, email, telecopy or by registered or certified
mail, return receipt requested, addressed to the Company’s General Counsel at its principal office, or at such other office
as the Company may from time to time designate in writing. The date of actual delivery of any notice under this Section 13
shall be deemed to be the date of delivery thereof.


 


14.      Waiver; Severability. No provision of this
Agreement may be amended or waived unless such amendment or waiver is agreed to by you and the Company in a writing that specifically
references this Section 14 . No waiver by you or the Company of the breach of any condition or provision of this Agreement will
be deemed a waiver of a similar or dissimilar provision or condition at the same or any prior or subsequent time. Except as expressly
provided herein to the contrary, failure or delay on the part of either party hereto to enforce any right, power, or privilege
hereunder will not be deemed to constitute a waiver thereof. In the event any portion of this Agreement is determined to be invalid
or unenforceable for any reason, the remaining portions shall be unaffected thereby and will remain in full force and effect to
the fullest extent permitted by law.


 






    	7



    	 



    

 





15.      Voluntary Agreement, Nondisparagement.
Each party represents that it has the power and authority to enter into this Agreement. Each party acknowledges that it has been
advised to review this Agreement with its own legal counsel and other advisors of its choosing and that prior to entering into
this Agreement, each has had the opportunity to review this Agreement with its attorney and other advisors and have not asked (or
relied upon) the other party or other party’s counsel to represent it in this matter. Each party further represents that
each has carefully read and understands the scope and effect of the provisions of this Agreement and that each is fully aware of
the legal and binding effect of this Agreement. This Agreement is executed voluntarily by each party and without any duress or
undue influence on the part or behalf of the other party. The Company agrees that the Board and its executive officers will not
make (or direct the Company or any of its affiliates, employees or agents to make) any written or oral communications that could
reasonably be considered to be disparaging of you (or your family members) in any respect including, but not limited to, your personal
performance, abilities or reputation.


 






    	8



    	 



    

 








Please acknowledge your acceptance and understanding of this
Agreement by signing and returning it to the undersigned. A copy of this signed Agreement will be sent to you for your records.


 


 


 


	ACKNOWLEDGED AND AGREED:	 	 
	 	 	 
	 	 	 
	INNOVUS PHARMACEUTICALS, INC.	 	BASSAM DAMAJ, Ph.D.
	 	 	 
	/s/Henry J. Esber, Ph.D.	 	/s/Bassam Damaj
	BY:       Henry J. Esber, Ph.D.	 	 
	TITLE:  Director	 	 


 






    	9



    	 



    

 


EXHIBIT A


 


R&D Healthcare, Inc.


 


Atlas Biotechnology Development


 






    	10



    	 



    

 








Exhibit
B


 


MUTUAL RELEASE OF ALL CLAIMS AND COVENANT
NOT TO SUE PURSUANT

TO AGREEMENT


 


1.      PARTIES.
The parties to this Agreement and Release are Bassam Damaj (“Executive”) and Innovus Pharmaceuticals, Inc., a Nevada
corporation, (the “Company”).


 


2.      RECITALS.
This Release is made with reference to the following facts: 


 


Executive and Company are parties to an Employment
Agreement dated January 22, 2013. That Employment Agreement provides that the Executive must execute a mutual general release and
covenant not to sue within not later than forty-five (45) days after Executive’s Termination Date (as defined in the Employment
Agreement) in order for Executive to receive the severance payment and benefits under the Employment Agreement. This Release is
the mutual general release and covenant not to sue required by the Employment Agreement.


 


3.      EXECUTIVE’S
PROMISES. In consideration for the promises and payments contained in the Employment Agreement, each party agrees as follows:


 


3.1      Executive hereby covenants not to
sue and also waives, releases and forever discharges Company, its parent company, divisions, subsidiaries, officers, directors,
agents, employees, stockholders, affiliates and successors from any and all claims, causes of action, damages or costs of any type
Executive may have against Company or its current and former parent company, divisions, subsidiaries, officers, directors, employees,
agents, stockholders, successors or affiliates (the “Released Parties”), and the Released Parties similarly covenant
not to sue and also waive, release and forever discharge Executive from any and all claims, causes of action, damages or costs
of any type that the Released Parties may have against Executive, including without limitation those arising out of or relating
to Executive’s employment with Company, or Executive’s separation of employment. This waiver and release includes,
but is not limited to, claims, causes of action, damages or costs arising under or in relation to Company’s employee handbook
and personnel policies, or any oral or written representations or statements made by officers, directors, employees or agents of
Company, or under any state or federal law regulating wages, hours, compensation or employment, or any claim for breach of contract
or breach of the implied covenant of good faith and fair dealing, or any claim for stock, stock options, warrants, or phantom stock
or equity of any kind or any claim for wrongful termination, or any discrimination claim on the basis of race, sex, sexual orientation,
gender, age, religion, marital status, national origin, physical or mental disability, medical condition, or any claim arising
under the federal Age Discrimination in Employment Act, the Equal Pay Act, the California Family Rights Act, the Pregnancy Discrimination
Act, the Family Medical Leave Act, the California Labor Code, the California Wage Orders, Title VII of the Civil Rights Act, the
Fair Employment and Housing Act, the California Labor Code Private Attorneys General Act of 2004, the California Wage Orders, and
Business and Professions Code Section 17200, et seq.


 


Notwithstanding the foregoing, with respect
to Executive’s release, this Release does not release (a) claims that cannot be released as a matter of law, (b) claims
arising after the effective date of this Release including those under the Employment Agreement, (c) claims to enforce any of Executive’s
rights to post-termination benefits provided by the Employment Agreement, (d) claims for indemnification or coverage under a directors
and officers liability insurance policy as provided in the Employment Agreement or under any other contract or under applicable
law, (e) claims to enforce any of Executive’s vested benefits under any employee benefit plan of the Company including without
limitation his Compensatory Equity (as defined in the Employment Agreement), (f) Executive’s right to file a charge, testify,
assist, or cooperate with the EEOC or to file a claim under the Fair Labor Standards Act, or (g) Executive’s rights arising
solely as a shareholder of the Company.


 


3.2      The waiver and release set forth
in paragraph 3.1 applies to claims of which either party does not currently have knowledge and each party specifically waives the
benefit of the provisions of Section 1542 of the Civil Code of the State of California which reads as follows: “A general
release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing
the release, which if known by him or her must have materially affected his or her settlement with the debtor.”


 






    	11



    	 



    

  


4.      CONSULTATION,
REVIEW, AND REVOCATION. In accordance with the Age Discrimination in Employment Act of 1967 (“ADEA”) as amended
by the Older Workers Benefit Protection Act, Executive is advised to consult with an attorney before signing this Release. Executive
is given a period of 45 days in which to consider whether to enter into this Release. Executive does not have to utilize the entire
45 day period before signing this Release, and may waive this right. If Executive does enter into this Release, he may revoke the
Release within 7 days after the execution of the Release. Any revocation must be in writing and must be received by the Company
no later than midnight of the seventh day after execution by Executive. The Release is not effective or enforceable until after
this 7-day period has passed without revocation.


 


5.      MISCELLANEOUS.


 


5.1      This Release shall be deemed to have
been executed and delivered within the State of California, and the rights and obligations of the parties hereunder shall be construed
and enforced in accordance with, and governed by, the laws of the State of California.


 


5.2      This Release is the entire agreement
between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements
and discussions. This Release may be amended only by an agreement in a writing signed by the parties.


 


5.3      This Release is binding upon and
shall inure to the benefit of the parties hereof, their respective agents, employees, representatives, officers, directors, divisions,
subsidiaries, affiliates, parent company, assigns, heirs, partners, successors in interest and stockholders, including any successor
company of the Company.


 


5.4      Each party agrees that it has read
this Release and has had the opportunity to ask questions, seek counsel and time to consider the terms of the Release. Each party
has entered into this Release freely and voluntarily.


 


5.5      The parties agree that any dispute
or controversy arising from or related to this Release shall be decided by final and binding arbitration as provided in the Employment
Agreement.


 


 


 


	
        BASSAM DAMAJ (“Executive”)

         

        _______________________________

         

         

         

        Date:___________________________

         
	
        INNOVUS PHARMACEUTICALS INC. (“Company”)

         

        By:___________________________________

         

        Its:___________________________________

         

        Date:___________________________________

         



 






    	12